Capricor Therapeutics的股价在其杜氏肌营养不良症药物达成关键试验目标后暴涨500%，扭转了此前FDA的拒绝。 Capricor Therapeutics' stock surged 500% after its Duchenne muscular dystrophy drug met key trial goals, reversing an earlier FDA rejection.

在对杜申肌肉发育不良的细胞治疗药物德拉米欧塞尔进行的第3期HOPE-3试验后,Capricor Therapeutics的股票升至500%,达到其主要和次要终点,显示心脏功能显著改善. Capricor Therapeutics' stock soared up to 500% after its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy, met its primary and secondary endpoints, showing significant improvement in heart function. 积极的结果扭转了2024年7月林业发展局驳回其批准申请时以前遇到的挫折。 The positive results reversed a previous setback when the FDA rejected its approval application in July 2024. 该公司立即启动了一项公共股权提议,以发挥投资者信心的杠杆作用。 The company immediately launched a public equity offering to leverage the renewed investor confidence. 与此同时,NEXTDC与OpenAI签署了一项协议,在悉尼兴建一个超大规模的AI校园, Meanwhile, NEXTDC signed a deal with OpenAI to build a hyperscale AI campus in Sydney, boosting its shares 8% amid optimism over Australia’s sovereign AI infrastructure. 在采矿方面,关键资源公司在新西兰和澳大利亚推进了Cap Burn和Amoco项目,取得了有前途的钻探结果,并计划扩大勘探范围。 In mining, Critical Resources advanced its Cap Burn and Amoco projects in New Zealand and Australia, with promising drill results and plans for expanded exploration.